(Z)-4-(4-acetoaminophenylmethylene)-3-methyl-5(4H)-isoxazolone | 17975-67-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (Z)-4-(4-acetoaminophenylmethylene)-3-methyl-5(4H)-isoxazolone
• 英文别名: 4-(4-acetylamino-benzylidene)-3-methyl-4H-isoxazol-5-one；N-[4-[(Z)-(3-methyl-5-oxo-1,2-oxazol-4-ylidene)methyl]phenyl]acetamide
• CAS: 17975-67-6
• 化学式: C₁₃H₁₂N₂O₃
• 分子量: 244.25
• InChiKey: PAVHPPDUDYRCRU-GHXNOFRVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  67.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-乙酰苯胺 在 磷酸 、 羟胺 、 三氯氧磷 作用下， 生成 (Z)-4-(4-acetoaminophenylmethylene)-3-methyl-5(4H)-isoxazolone
  参考文献：
  名称：

  Novel Non-Steroidal/Non-Anilide Type Androgen Antagonists with an Isoxazolone Moiety

  摘要：

  3-Substitutcd (Z)-4-(4-N,N-dialkylaminophenylmethylene)-5(4H)-isoxazolones and related compounds were designed and prepared as candidates for structurally novel androgen antagonists. Several compounds showed potent anti-androgenic activity as assessed by nuclear androgen receptor binding assay and growth inhibition assay using androgen-dependent Shionogi carcinoma cells SC-3. They were approximately 10-220 times more potent than flutamide in these assay systems, They also showed anti-androgenic activity toward prostate tumor cell line LNCaP, which has an aberrant nuclear androgen receptor. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(01)00421-7

文献信息

• Novel Non-Steroidal/Non-Anilide Type Androgen Antagonists with an Isoxazolone Moiety
  作者：Toshiyasu Ishioka、Asako Kubo、Yukiko Koiso、Kazuo Nagasawa、Akiko Itai、Yuichi Hashimoto

  DOI：10.1016/s0968-0896(01)00421-7

  日期：2002.5

  3-Substitutcd (Z)-4-(4-N,N-dialkylaminophenylmethylene)-5(4H)-isoxazolones and related compounds were designed and prepared as candidates for structurally novel androgen antagonists. Several compounds showed potent anti-androgenic activity as assessed by nuclear androgen receptor binding assay and growth inhibition assay using androgen-dependent Shionogi carcinoma cells SC-3. They were approximately 10-220 times more potent than flutamide in these assay systems, They also showed anti-androgenic activity toward prostate tumor cell line LNCaP, which has an aberrant nuclear androgen receptor. (C) 2002 Elsevier Science Ltd. All rights reserved.